Search Medical Condition
Please enter condition
Please choose location
 

Marseille Cedex 01, France Clinical Trials

A listing of Marseille Cedex 01, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (440) clinical trials

Assessment of SpondyloArthritis Society (ASAS) Classification and Diagnostic Criteria for Early Axial Spondyloarthritis (SpA)

Background: Existing criteria for AS/SpA such as mod. New York, ESSG, or Amor criteria for classification and/or diagnosis of spondyloarthritis have limitations when applied to early disease. Moreover, MRI is not part of any of the established criteria and the precise role of MRI in early axial disease has not ...

Phase N/A

0.0 miles

Learn More »

Bortezomib and Low Dose Cytarabine in the Treatment of High-Risk Myelodysplastic Syndromes

Four cycles of treatment are proposed at 28 day intervals in an ambulatory setting Cycle 1 : - Cytarabine 10 mg /m2/day subcutaneous injection for 14 days - Bortézomib 1,5mg/m2 days 1,4,8,11 Cycles 2, 3, 4 : - Cytarabine 20 mg /m2/j subcutaneous injections for 14 days - Bortézomib 1,5mg/m2 ...

Phase

0.0 miles

Learn More »

Second-line Treatment in Patients With Small Cell Lung Cancer (SCLC)

Determined treatment efficacy and tolerability of second-line treatment in patients with small cell lung cancer comparing oral combinaison chemotherapy with intravenous combination chemotherapy.

Phase

0.0 miles

Learn More »

Lenalidomide in Subjects With intermediate2 or High MDS Associated With a Deletion (DEL) 5q [31]

Subjects meeting all inclusion and exclusion criteria will receive lenalidomide lenalidomide will be administered at 10 mg (two 5 mg capsules) once daily on Days 1–21, every 4 weeks. Bone marrow aspirate (baseline and during the course of the study at week 8, 16, 32, 52 and when clinically indicated/for ...

Phase

0.0 miles

Learn More »

Darbepoetin Alpha in Myelodysplastic Syndromes (MDS)

Inclusion of MDS with IPSS low or int-1 and hemoglobin < 10/dL. Study drug: Darbepoetin alfa (Aranesp) 500 microg every two weeks subcutaneously during 12 weeks, combined to filgrastim 300 microg twice weekly for an additional 12 weeks in non responders. Response will be evaluated at 12 weeks. Patients with ...

Phase

0.0 miles

Learn More »

Inflammatory Breast Cancer (IBC) Registry

IBC IBC is a rare but rapidly growing form of breast cancer. Currently, there are no known risk factors and biological features (such as in the genes) that researchers can use to help design better treatments for IBC. Study Participation: If you are diagnosed with IBC or the doctor believes ...

Phase N/A

0.0 miles

Learn More »

Evaluation of Therapeutic Strategies for Treatment of Ectopic Pregnancies (EP) and Evaluation of Subsequent Fertility

The first group includes non active ectopic pregnancies defined by score or algorithm. In this case, we propose a randomized controlled trial between medical and conservative surgery. In all others clinical situations, we proposed surgery treatment. In a randomized controlled trial we compare conservative versus radical treatment. The patients are ...

Phase

0.0 miles

Learn More »

SPATAX: Clinical and Genetic Analysis of Cerebellar Ataxias and Spastic Paraplegias

Cerebellar ataxias (CA) and spastic paraplegias (SP) are genetically and clinically very heterogeneous. More than 40 loci are already known but the number of phenotypes is even greater suggesting further genetic heterogeneity. These progressive disorders are often severe and fatal, due to the absence of specific therapy. The SPATAX network ...

Phase

0.0 miles

Learn More »

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Due to anti-arrhythmic pharmacological drugs failure to suppress atrial fibrillation (AF), interest towards preventive pacing treatments is increasing. The importance of this option in the panoply of the preventive tools is fully justified, only by considering the insufficiency, the complexity, or the poor reproducibility of the other non-pharmaceutical approaches. Preventive ...

Phase

0.0 miles

Learn More »

Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products

All Medtronic market-released leads and all market-released IPG, ICD and CRT devices are eligible to be included in this study.

Phase N/A

0.0 miles

Learn More »